Table 3.
COTΔ1 | COTΔ2 | NICΔ1 | NICΔ2 | NNALΔ1 | NNALΔ2 | 2HPMAΔ1 | 3HPMAΔ1 | AAMAΔ1 | CNEMAΔ1 | MHBMAΔ1 | HEMAΔ1 | PMAΔ1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
COTΔ1 | l | 0.90*** | 0.19 | 0.44*** | 0.73*** | 0.75*** | –0.04 | 0.29* | 0.74*** | 0.84*** | 0.10 | 0.65*** | 0.92*** |
COTΔ2 | 1 | 0.09 | 0.51*** | 0.71*** | 0.78*** | –0.08 | 0.23 | 0.73*** | 0.86*** | 0.09 | 0.67*** | 0.92*** | |
NICΔ1 | 1 | 0.52*** | 0.09 | 0.12 | –0.17 | 0.18 | 0.06 | 0.08 | 0.06 | 0.23 | 0.01 | ||
NICΔ2 | 1 | 0.59*** | 0.66*** | –0.01 | 0.42** | 0.53*** | 0.43*** | 0.09 | 0.31* | 0.35** | |||
NNALΔ1 | 1 | 0.94*** | 0.34** | 0.36** | 0.76*** | 0.70*** | 0.08 | 0.33* | 0.64*** | ||||
NNALΔ2 | 1 | 0.09 | 0.42** | 0.86*** | 0.79*** | 0.10 | 0.44*** | 0.69*** | |||||
2HPMAΔ1 | 1 | –0.10 | –0.03 | –0.13 | –0.07 | –0.34* | –0.10 | ||||||
3HPMAΔ1 | 1 | 0.27* | 0.24 | 0.16 | 0.24 | 0.35** | |||||||
AAMAΔ1 | 1 | 0.85*** | 0.09 | 0.45*** | 0.68*** | ||||||||
CNEMAΔ1 | 1 | 0.12 | 0.64*** | 0.82*** | |||||||||
MHBMAΔ1 | 1 | 0.30* | 0.14 | ||||||||||
HEMAΔ1 | 1 | 0.70*** | |||||||||||
PMAΔ1 | 1 |
All subjects included in the analysis; COT = cotinine; NIC = nicotine; NNAL = 4–(methylritrosamino)–1–(3–pyridyl)–1–butanol; VOC mercapturic acid metabolites (parent compound in parenthesis): 2HPMA=2-hydroxypropyl (propylene oxide), 3-HPMA=3-hydroxypropyl (acrolein), AAMA=2-carbamoylethyl (acrylamide), CNEMA=cyanoethyl (acrylonitrile), MHBMA=2-hydroxy-3-buten-1-yl or isomer(s) (1,3-butadiene), HEMA=2-hydroxyethyl (ethylene oxide), and PMA=phenyl (benzene);
Δ1 = post minus pre-exposure; Δ2 = nextday minus pre-exposure; VOC mercapturic acid metabolites were only measured in pre-exposure and post-exposure samples;
p < 0.05
p < 0.01
p < 0.001